Medscape Conference Coverage, based on selected sessions at:

ICAD 2008: Alzheimer's Association International Conference on Alzheimer's Disease

July 26 - 31, 2008; Chicago, Illinois

This activity is not sanctioned by, nor a part of, the Alzheimer's Association. Conference news does not receive grant support and is produced independently.

Conference News

  • Experimental Agent Safe, May "Dissolve" Plaques in Mild to Moderate AD

    Interim results of a phase 2 study testing an experimental monoclonal antibody that targets amyloid beta indicate it is safe, well tolerated, and may be able to "dissolve" amyloid plaques in the brains of patients with mild-to-moderate Alzheimer's disease.
    Medscape Medical News, August 8, 2008
  • Novel Agent Produces Sustained Benefit in Mild to Moderate AD

    New data from an open-label 6-month extension trial of Dimebon, an agent with a novel neuroprotective effect, indicates the drug may have sustained clinical benefit in mild-to-moderate Alzheimer's disease.
    Medscape Medical News, August 7, 2008
  • Unexpectedly High Rates of MCI Could Overwhelm Future Health Resources

    Unexpectedly high rates of mild cognitive impairment, widely considered to be a prodromal phase of Alzheimer's disease and other dementias, have been found in a large population-based study of elderly patients.
    Medscape Medical News, August 6, 2008
  • Tau-Based Therapy Arrests Disease Progression

    New research suggests that a treatment that targets neurofibrillary tangles arrests disease progression and improves cognitive function in patients with mild-to-moderate Alzheimer's disease.
    Medscape Medical News, August 1, 2008
  • Tarenflurbil: No Effect in Early AD

    Full final results from one of the largest phase 3 clinical trials to date testing a potentially disease-modifying agent in mild Alzheimer's disease confirm that tarenflurbil, a gamma-secretase inhibitor, did not lead to and improvement in either cognition or activities of daily living.
    Medscape Medical News, August 1, 2008
  • Combination Insulin and Oral Diabetes Drugs

    A new study suggests that combination therapy with insulin and other oral antidiabetes drugs is associated with a significant reduction in the density of neuritic plaques in the brains of patients with type 2 diabetes.
    Medscape Medical News, July 30, 2008
  • Experimental Agent Improves Memory in MCI

    An experimental amino acid peptide that targets neurofibrillary tangles appears to improve memory in patients with amnestic mild cognitive impairment.
    Medscape Medical News, July 30, 2008
  • Phase 2a Trial of PBT2 in AD Supports Further Investigation

    Results of a phase 2a trial of PBT2, a metal-protein-attenuating compound, show that over 12 weeks of administration, the drug was safe and well tolerated in patients with Alzheimer's disease.
    Medscape Medical News, July 30, 2008
  • Physical Fitness and Alzheimer's Disease

    A new study shows that cardiorespiratory fitness is associated with hippocampal and parahippocampal volumes in those with early AD but not with dementia. In separate studies, AD patients who did caregiver-directed exercise had a reduction in falls and an increase in quality of life.
    Medscape Medical News, July 29, 2008
  • Early Detection and Diagnosis of AD

    Three new studies indicate that emerging diagnostic imaging techniques are bringing medical science closer to the early detection and diagnosis of Alzheimer's disease.
    Medscape Medical News, July 29, 2008
  • ICAD to Become an Annual Event

    In response to the increasing population of AD patients and a burgeoning research climate, the Alzheimer's Association is making their premier meeting, the International Conference on Alzheimer's Disease, normally held every other year, an annual event.
    Medscape Medical News, July 29, 2008

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the Alzheimer's Association. These materials and the related activity are not sanctioned by the Alzheimer's Association or the commercial supporter of the conference and do not constitute an official part of that conference.